Format

Send to

Choose Destination
Proc Natl Acad Sci U S A. 2018 Jan 16;115(3):561-566. doi: 10.1073/pnas.1717776115. Epub 2018 Jan 2.

Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy.

Author information

1
Department of Cell Biology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02215.
2
Department of Cancer Biology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02215.
3
Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114.
4
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02215.
5
Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL 33458.
6
Department of Cell Biology, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02215; Bruce_Spiegelman@dfci.harvard.edu.

Abstract

The peroxisome-proliferator receptor-γ (PPARγ) is expressed in multiple cancer types. Recently, our group has shown that PPARγ is phosphorylated on serine 273 (S273), which selectively modulates the transcriptional program controlled by this protein. PPARγ ligands, including thiazolidinediones (TZDs), block S273 phosphorylation. This activity is chemically separable from the canonical activation of the receptor by agonist ligands and, importantly, these noncanonical agonist ligands do not cause some of the known side effects of TZDs. Here, we show that phosphorylation of S273 of PPARγ occurs in cancer cells on exposure to DNA damaging agents. Blocking this phosphorylation genetically or pharmacologically increases accumulation of DNA damage, resulting in apoptotic cell death. A genetic signature of PPARγ phosphorylation is associated with worse outcomes in response to chemotherapy in human patients. Noncanonical agonist ligands sensitize lung cancer xenografts and genetically induced lung tumors to carboplatin therapy. Moreover, inhibition of this phosphorylation results in deregulation of p53 signaling, and biochemical studies show that PPARγ physically interacts with p53 in a manner dependent on S273 phosphorylation. These data implicate a role for PPARγ in modifying the p53 response to cytotoxic therapy, which can be modulated for therapeutic gain using these compounds.

KEYWORDS:

DNA damage; PPARγ; chemotherapy; lung cancer

PMID:
29295932
PMCID:
PMC5776997
DOI:
10.1073/pnas.1717776115
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center